Key Highlights for Investors

• Buyback Details: The board has authorized a repurchase of up to \$1 million in common stock. Repurchases may occur via open market purchases, privately negotiated transactions, or other approved methods in compliance with SEC regulations.
• Outstanding Shares: As of November 13, 2025, Silo Pharma reported 13,318,273 shares of common stock outstanding.
• Strategic Intent: CEO Eric Weisblum emphasized that current capital market conditions are favorable for capturing additional shareholder value through this measured buyback program. The board and management are committed to enhancing shareholder returns.
• Flexibility: The company is not obligated to repurchase any specific number of shares. The program may be suspended or discontinued at any time, at the company’s discretion.
• Price Sensitivity: The timing, volume, and price of repurchases will depend on market conditions and regulatory limitations, including blackout period restrictions.

Potential Impact on Shareholders and Share Price

• Shareholder Value: Share buybacks are typically viewed as positive for shareholders as they can reduce the number of shares outstanding, potentially increasing earnings per share and supporting the share price.
• Market Conditions: The decision to initiate the buyback program reflects management’s confidence in the company’s value and outlook, potentially signaling to investors that shares may be undervalued.
• Discretionary Nature: Since the company can suspend or discontinue the program at any time, investors should monitor future disclosures for updates on buyback activity.
• Regulatory Compliance: All repurchases will be conducted in accordance with SEC rules and other applicable legal requirements, ensuring transparency and compliance.

Company Overview

Silo Pharma’s core focus is on merging traditional therapeutics with psychedelic research to address underserved conditions such as stress-induced psychiatric disorders, chronic pain, and CNS diseases. The company’s pipeline includes:

• SPC-15: Targeting PTSD
• SP-26: Targeting fibromyalgia and chronic pain
• Preclinical Assets: Targeting Alzheimer’s disease and multiple sclerosis

Silo Pharma collaborates with leading universities and laboratories for its research and development initiatives.

Forward-Looking Statements

The press release contains forward-looking statements, which are subject to risks and uncertainties. These include, but are not limited to, changes in anticipated revenue sources, economic and competitive conditions, difficulties in developing technology platforms, retaining and expanding the customer base, and fluctuations in consumer spending. There is no assurance that outcomes will align with management’s expectations.

Contact Information

Investor Relations:
Phone: (800) 705-0120
Email: [email protected]

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions. The information is based on company disclosures and may be subject to change without notice.